@entity309 ( @entity309 ) is a @entity66 and its renal involvement, relatively common, is clinically significant because worsens course and mortality of the @entity66 . There is still no agreement on the prevalence of @entity8 in @entity309 : data analysis originates from different sources, as death certificates, autopsies, clinical and laboratory findings and kidney biopsies, each with its limitations. Histoimmunological studies on bioptical specimens of @entity1 with @entity8 , led to clarify prevalent pathologies. In order of frequency: @entity631 and @entity2783 (60-65% and 20-30% respectively), followed by acute or chronic @entity1986 . @entity8 during @entity309 includes @entity12042 , nephrotoxic effects of antirheumatic drugs and @entity8 as extra-articular manifestations ( @entity8 ). @entity2783 affects survival, increases morbidity and is the main cause of end stage @entity8 in @entity1 with @entity309 and @entity8 . Strong association between @entity309 activity and @entity2783 needs the use of immunosuppressive and combined therapies, to prevent this complication and reduce risk of dialysis. Long-lasting and combined @entity309 pharmacotherapy involves various renal side effects. In this review we describe NSAIDs and DMARDs (Disease-Modifying Antirheumatic Drugs) nephrotoxicity, particularly by gold compounds, @entity2361 , @entity205 and @entity1499 . Rare cases of IgA @entity631 during immunomodulating therapy with @entity6963 and TNF blocking receptor (etanercept) are reported; real clinical significance of this drug-related @entity8 will be established by development of @entity309 treatment. In @entity309 @entity8 , @entity631 is the most frequent histological lesion (35-60 % out of biopsies from @entity1 with @entity8 ), followed by @entity1987 (3-14%) and p-ANCA positive necrotizing crescentic @entity631 .

[Kidney involvement in XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy', 'nephropathies', 'renal disorders', 'rheumatoid nephropathy', 'urinary abnormalities and/or kidney impairment', 'Kidney injury', 'RA and kidney damage', 'renal disease'] @entity12042 :: ('MESH:C538249', 'Disease') :: ['secondary renal amyloidosis'] @entity1987 :: ('MESH:D009402', 'Disease') :: ['minimal change glomerulopathy'] @entity66 :: ('MESH:D004194', 'Disease') :: ['widespread disease', 'primary disease'] @entity6963 :: ('MESH:C045463', 'Chemical') :: ['leflunomide'] @entity2783 :: ('MESH:D000686', 'Disease') :: ['Amyloidosis', 'amyloidosis'] @entity2361 :: ('MESH:D010396', 'Chemical') :: ['D-penicillamine'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine A'] @entity1986 :: ('MESH:D009395', 'Disease') :: ['interstitial nephritis'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate'] @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis', 'mesangial glomerulonephritis'] @entity309 :: ('MESH:D001172', 'Disease') :: ['Rheumatoid Arthritis', 'RA']
@entity309 :: (MESH:D001172,Disease) :: ['rheumatoid arthritis']
